Autologous dendritic cells (DC) loaded with autologous tumor homogenate, 10 x7 cells ID every 3 weeks for up to six doses. Pembrolizumab 200 mg IV q3w.Interleukin-2 3 MU s.c. from day +2 to day +6 after each DC administration. This evidence concerns the gene IL2 and neoplasm.